向DHODH揭示了ATRA耐药性急性肌肉细胞白血病的治疗机会

向DHODH揭示了ATRA耐药性急性肌肉细胞白血病的治疗机会

相关实验视频

Updated: Jul 19, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

Tingyuan Yang¹, Xiayu Shi¹, Shiliang Li¹

¹Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

|August 14, 2023

概括

用化合物416抑制二罗酸脱酶 (DHODH) 克服了急性前兆细胞白血病 (APL) 中的全转网红酸 (ATRA) 抵抗. 这种DHODH抑制剂显示出治疗耐火性和复发性APL的潜力.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

全转录氨酸 (ATRA) 已大大改善了急性肌肉细胞白血病 (APL) 治疗结果.
高风险APL患者的ATRA耐药性仍然是一个重大的临床挑战.

研究的目的:

作为一种克服APLATRA耐药性的策略,研究二基酸脱酶 (DHODH) 抑制.
评估一种新型DHODH抑制剂416在对抗ATRA耐药APL的疗效和机制.

主要方法:

在APL细胞系和动物模型中利用了一种强大的DHODH抑制剂 (416).
评估了416对APL细胞亡,分化和关键蛋白调节 (Bcl-2,c-Myc) 的影响.
研究了ATRA耐药性背后的分子机制和DHODH抑制的影响.

主要成果:

化合物416在试验室和体内证明了抑制APL发生的有效性.
416通过诱导耐药APL细胞的亡和分化,有效地克服了ATRA耐药性.
通过416抑制DHODH,恢复了Bcl-2和c-Myc的调节,这些细胞在耐ATRA细胞中失调.

结论:

DHODH抑制,特别是与化合物416的抑制,为克服APL中的ATRA抵抗提供了一个有希望的治疗方法.
这些发现支持对耐火性和复发性APL患者的DHODH抑制剂的进一步临床开发.

关键词:

在APL中,APL是APL.在ATRA的阻力方面,它具有很强的阻力.生物评估生物评估 DHODH DHODH 在线阅读作用机制作用机制

更多相关视频

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

174

相关概念视频

02:57

Targeted Cancer Therapies

7.7K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.7K

Combination Therapies and Personalized Medicine

02:50

Combination Therapies and Personalized Medicine

4.9K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...